Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorpromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.86 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.86 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.86 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.86 |
| ▸ | HTR1A | P08908 | 6/20 | 0.86 |
| ▸ | LMNA | P02545 | 6/20 | 0.86 |
| ▸ | TP53 | P04637 | 6/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.86 |
| ▸ | MAPT | P10636 | 5/20 | 0.86 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.86 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.86 |
| ▸ | DRD1 | P21728 | 5/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.86 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.86 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorpromazine SCHEMBL29358018 | 0.93 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNATP53 | |
| Chlorpromazine SCHEMBL8321 | 0.93 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNATP53 | |
| Chlorpromazine SCHEMBL29367385 | 0.93 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNATP53 | |
| Chlorpromazine SCHEMBL29351728 | 0.92 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNATP53 | |
| Chlorpromazine SCHEMBL29714121 | 0.92 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNATP53 | |
| Chlorpromazine SCHEMBL23326209 | 0.92 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNATP53 | |
| Chlorpromazine SCHEMBL27869706 | 0.92 | CYP1A2 (0.97) | CYP1A2CYP2D6HTR1ALMNATP53 | |
| Chlorpromazine SCHEMBL5483904 | 0.92 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNATP53 | |
| Chlorpromazine SCHEMBL41771 | 0.92 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNATP53 | |
| Chlorpromazine SCHEMBL8503036 | 0.92 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382328-B2 | Rapid drug discovery methods for pathogen inactivation | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
| US-20200305423-A1 | RAPID DRUG DISCOVERY METHODS FOR PATHOGEN INACTIVATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-10-01 | — | — | US | disclosed |
| CN-108025008-A | Compositions and methods for treating substance use disorders, addiction and psychosis | 安比拉神经疗法公司 | 2018-05-11 | — | — | CN | disclosed |
| US-20170266292-A1 | LIPIDIC COMPOUND-TELODENDRIMER HYBRID NANOPARTICLES AND METHODS OF MAKING AND USES THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2017-09-21 | — | — | US | disclosed |
| US-8383617-B2 | Treatment of protein aggregation diseases | PAD PHARMA LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| CN-1809357-B | Small molecule Toll-like receptor (TLR) antagonists | COLEY PHARM GMBH | 2010-12-22 | — | — | CN | disclosed |
| US-20100035859-A1 | TREATMENT OF PROTEIN AGGREGATION DISEASES | PAD PHARMA LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-02-11 | — | — | US | disclosed |
| US-7592457-B2 | 3-aryl-3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-09-22 | — | — | US | disclosed |
| US-20090203708-A1 | NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-08-13 | — | — | US | disclosed |
| US-20060084676-A1 | 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-04-20 | — | — | US | disclosed |
| EP-1635846-A2 | SMALL MOLECULE TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS | Coley Pharmaceutical GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050119273-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005046667-A2 | SYSTEM A TRANSPORT INHIBITORS FOR TREATING OR PREVENTING NEUROPSYCHIATRIC DISORDERS | RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005007672-A2 | SMALL MOLECULE TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS | COLEY PHARMACEUTICAL GMBH (DE) | 2005-01-27 | — | — | WO | disclosed |
| US-5223530-A | Selective high-affinity ligands for treatment of psychological disorders, side effect reduction | SRI, INTERNATIONAL (US) | 1993-06-29 | — | — | US | disclosed |
| WO-1993010266-A1 | DEVICE AND METHOD FOR DETECTION OF COMPOUNDS WHICH INTERCALATE WITH NUCLEIC ACIDS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1993-05-27 | — | — | WO | disclosed |
| EP-0495084-A1 | ARYLCYCLOALKANEPOLYALKYLAMINES | SRI INTERNATIONAL (US) | 1992-07-22 | — | — | EP | disclosed |
| WO-1992002481-A1 | ARYLCYCLOALKANEPOLYALKYLAMINES | SRI INTERNATIONAL (US) | 1992-02-20 | — | — | WO | disclosed |
| US-5086054-A | Selective high-affinity ligands to sigma boding sites, administering, amipsychotic, antiarrhythmia, antiischemic agents anticonvulsants, reduced side effects | SRI INTERNATIONAL (US) | 1992-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119273-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | DRD2 875/4885DRD3 1063/4885DRD4 1246/4885 |
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OPRD1, HTR6, HTR1D | DRD2 8/4885DRD3 18/4885DRD4 20/4885 |
| US-20060084676-A1 | 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same | HTR6, HTR3B, HTR2C | DRD2 34/4885DRD3 78/4885DRD4 69/4885 |
| US-20100035859-A1 | TREATMENT OF PROTEIN AGGREGATION DISEASES | PRNP, TTR, HTT | DRD2 4749/4885DRD3 4764/4885DRD4 4776/4885 |
| US-20090203708-A1 | NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR5A, HTR3B, HTR1A | DRD2 46/4885DRD3 118/4885DRD4 126/4885 |
| US-20170266292-A1 | LIPIDIC COMPOUND-TELODENDRIMER HYBRID NANOPARTICLES AND METHODS OF MAKING AND USES THEREOF | CETP, MTTP, STARD3 | DRD2 3881/4885DRD3 2739/4885DRD4 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.